NextCure Inc has a consensus price target of $6.6, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Needham, and Needham on March 22, 2024, March 20, 2024, and December 14, 2023. With an average price target of $5.33 between HC Wainwright & Co., Needham, and Needham, there's an implied 253.20% upside for NextCure Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/22/2024 | NXTC | Buy Now | NextCure | $1.51 | 429.8% | HC Wainwright & Co. | Emily Bodnar | $5 → $8 | Maintains | Buy | Get Alert |
03/20/2024 | NXTC | Buy Now | NextCure | $1.51 | 164.9% | Needham | Gil Blum | $4 → $4 | Maintains | Buy | Get Alert |
12/14/2023 | NXTC | Buy Now | NextCure | $1.51 | 164.9% | Needham | Gil Blum | $6 → $4 | Maintains | Buy | Get Alert |
08/08/2023 | NXTC | Buy Now | NextCure | $1.51 | 363.58% | HC Wainwright & Co. | Emily Bodnar | → $7 | Initiates | → Buy | Get Alert |
08/04/2023 | NXTC | Buy Now | NextCure | $1.51 | 297.35% | Needham | Gil Blum | → $6 | Reiterates | Buy → Buy | Get Alert |
05/05/2023 | NXTC | Buy Now | NextCure | $1.51 | 297.35% | Needham | Gil Blum | → $6 | Reiterates | → Buy | Get Alert |
03/03/2023 | NXTC | Buy Now | NextCure | $1.51 | 297.35% | Needham | Gil Blum | → $6 | Reiterates | → Buy | Get Alert |
11/04/2022 | NXTC | Buy Now | NextCure | $1.51 | — | Ladenburg Thalmann | Aydin Huseynov | — | Downgrade | Buy → Neutral | Get Alert |
11/04/2022 | NXTC | Buy Now | NextCure | $1.51 | 297.35% | Needham | Gil Blum | $12 → $6 | Maintains | Buy | Get Alert |
11/04/2022 | NXTC | Buy Now | NextCure | $1.51 | 297.35% | Piper Sandler | Edward Tenthoff | $13 → $6 | Maintains | Overweight | Get Alert |
08/23/2022 | NXTC | Buy Now | NextCure | $1.51 | 893.38% | Truist Securities | Asthika Goonewardene | $19 → $15 | Maintains | Buy | Get Alert |
05/23/2022 | NXTC | Buy Now | NextCure | $1.51 | 760.93% | Piper Sandler | Edward Tenthoff | $21 → $13 | Maintains | Overweight | Get Alert |
03/01/2022 | NXTC | Buy Now | NextCure | $1.51 | 959.6% | Ladenburg Thalmann | Aydin Huseynov | → $16 | Initiates | → Buy | Get Alert |
11/05/2021 | NXTC | Buy Now | NextCure | $1.51 | 827.15% | Needham | Gil Blum | — | Maintains | Buy | Get Alert |
The latest price target for NextCure (NASDAQ: NXTC) was reported by HC Wainwright & Co. on March 22, 2024. The analyst firm set a price target for $8.00 expecting NXTC to rise to within 12 months (a possible 429.80% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for NextCure (NASDAQ: NXTC) was provided by HC Wainwright & Co., and NextCure maintained their buy rating.
There is no last upgrade for NextCure.
The last downgrade for NextCure Inc happened on November 4, 2022 when Ladenburg Thalmann changed their price target from N/A to N/A for NextCure Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on March 22, 2024 so you should expect the next rating to be made available sometime around March 22, 2025.
While ratings are subjective and will change, the latest NextCure (NXTC) rating was a maintained with a price target of $5.00 to $8.00. The current price NextCure (NXTC) is trading at is $1.51, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.